New pharmaceutical formulation comprising cannabidiol and tetrahydrocannabivarin

Roger Guy Pertwee (Inventor), Geoffrey W Guy (Inventor), Brian Whittle (Inventor)

Research output: Patent

Abstract

The present invention relates to a novel pharmaceutical formulation comprising a ratioed mix of: (i) one or more compounds that acts as an inverse agonist of the CB1 and/or CB2 receptor; and (ii) one or more compounds that acts as a neutral antagonist of the CB1 and/or CB2 receptor. Preferably both the inverse agonist of the CB1 and/or CB2 receptor and the neutral antagonist of the CB1 and/or CB2 receptor are cannabinoids. Preferably the cannabinoids are tetrahydrocannabidivarin (THCV) and cannabidiol (CBD).
Original languageEnglish
Patent numberWO2009007697
IPCA61K31/05; A61K31/352; A61K36/185; A61P19/08;
Publication statusPublished - 15 Jan 2009

Fingerprint

Cannabidiol
Cannabinoid Receptor CB2
Cannabinoid Receptor CB1
Drug Compounding
Cannabinoids

Cite this

Pertwee, R. G., Guy, G. W., & Whittle, B. (2009). IPC No. A61K31/05; A61K31/352; A61K36/185; A61P19/08;. New pharmaceutical formulation comprising cannabidiol and tetrahydrocannabivarin. (Patent No. WO2009007697).

New pharmaceutical formulation comprising cannabidiol and tetrahydrocannabivarin. / Pertwee, Roger Guy (Inventor); Guy, Geoffrey W (Inventor); Whittle, Brian (Inventor).

IPC No.: A61K31/05; A61K31/352; A61K36/185; A61P19/08;. Patent No.: WO2009007697.

Research output: Patent

Pertwee, RG, Guy, GW & Whittle, B 2009, New pharmaceutical formulation comprising cannabidiol and tetrahydrocannabivarin, Patent No. WO2009007697, IPC No. A61K31/05; A61K31/352; A61K36/185; A61P19/08;.
Pertwee RG, Guy GW, Whittle B, inventors. New pharmaceutical formulation comprising cannabidiol and tetrahydrocannabivarin. A61K31/05; A61K31/352; A61K36/185; A61P19/08;. 2009 Jan 15.
Pertwee, Roger Guy (Inventor) ; Guy, Geoffrey W (Inventor) ; Whittle, Brian (Inventor). / New pharmaceutical formulation comprising cannabidiol and tetrahydrocannabivarin. IPC No.: A61K31/05; A61K31/352; A61K36/185; A61P19/08;. Patent No.: WO2009007697.
@misc{aae648222de34149974609870b100b49,
title = "New pharmaceutical formulation comprising cannabidiol and tetrahydrocannabivarin",
abstract = "The present invention relates to a novel pharmaceutical formulation comprising a ratioed mix of: (i) one or more compounds that acts as an inverse agonist of the CB1 and/or CB2 receptor; and (ii) one or more compounds that acts as a neutral antagonist of the CB1 and/or CB2 receptor. Preferably both the inverse agonist of the CB1 and/or CB2 receptor and the neutral antagonist of the CB1 and/or CB2 receptor are cannabinoids. Preferably the cannabinoids are tetrahydrocannabidivarin (THCV) and cannabidiol (CBD).",
author = "Pertwee, {Roger Guy} and Guy, {Geoffrey W} and Brian Whittle",
year = "2009",
month = "1",
day = "15",
language = "English",
type = "Patent",
note = "WO2009007697; A61K31/05; A61K31/352; A61K36/185; A61P19/08;",

}

TY - PAT

T1 - New pharmaceutical formulation comprising cannabidiol and tetrahydrocannabivarin

AU - Pertwee, Roger Guy

AU - Guy, Geoffrey W

AU - Whittle, Brian

PY - 2009/1/15

Y1 - 2009/1/15

N2 - The present invention relates to a novel pharmaceutical formulation comprising a ratioed mix of: (i) one or more compounds that acts as an inverse agonist of the CB1 and/or CB2 receptor; and (ii) one or more compounds that acts as a neutral antagonist of the CB1 and/or CB2 receptor. Preferably both the inverse agonist of the CB1 and/or CB2 receptor and the neutral antagonist of the CB1 and/or CB2 receptor are cannabinoids. Preferably the cannabinoids are tetrahydrocannabidivarin (THCV) and cannabidiol (CBD).

AB - The present invention relates to a novel pharmaceutical formulation comprising a ratioed mix of: (i) one or more compounds that acts as an inverse agonist of the CB1 and/or CB2 receptor; and (ii) one or more compounds that acts as a neutral antagonist of the CB1 and/or CB2 receptor. Preferably both the inverse agonist of the CB1 and/or CB2 receptor and the neutral antagonist of the CB1 and/or CB2 receptor are cannabinoids. Preferably the cannabinoids are tetrahydrocannabidivarin (THCV) and cannabidiol (CBD).

M3 - Patent

M1 - WO2009007697

ER -